This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for vTv Therapeutics's Median PS Value or its related term are showing as below:
During the past 13 years, the highest Price to Median PS Value of vTv Therapeutics was 137.35. The lowest was 88.24. And the median was 112.80.
FRA:5VT0's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.62 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
vTv Therapeutics (FRA:5VT0) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
vTv Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
30.80
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
vTv Therapeutics Median PS Value Related Terms
vTv Therapeutics Median PS Value Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5VT0 vs CRDF, GUTS, ACOG: Median PS Value Comparison
For the Biotechnology subindustry, vTv Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
vTv Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.178.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
vTv Therapeutics (FRA:5VT0) has a Median PS Value of €0.00 as of Jun. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on vTv Therapeutics and its competitors. Over the past decade, vTv Therapeutics' Median PS Value has ranged from 88.24 to 137.35. According to the industry distribution chart, vTv Therapeutics ranks #999999 out of 276 companies in the Biotechnology industry.
Is vTv Therapeutics' Median PS Value too high?
vTv Therapeutics' current Median PS Value is €0.00. Over the past 10 years, this metric has ranged from a low of 88.24 to a high of 137.35. Based on the distribution chart, vTv Therapeutics ranks #999999 out of 276 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Median PS Value compare to CRDF and GUTS?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #999999 out of 276 companies for Median PS Value. This places vTv Therapeutics in the lower half of its industry. The industry median Median PS Value is 0.62. Historically, vTv Therapeutics' own Median PS Value has ranged from 88.24 to 137.35 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on vTv Therapeutics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. vTv Therapeutics's current Median PS Value is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Median PS Value of €0.00. The stock's GF Value™ is €6,491.15, compared to a current price of €30.80 — trading 99.5% below its estimated fair value. The current Median PS Value is €0.00. vTv Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Median PS Value is €0.00 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?
Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued.
The current stock price of €30.80 is trading 99.5% below its estimated GF Value™ of €6,491.15.
Key valuation signals for FRA:5VT0:
Median PS Value: €0.00
GF Value™: €6,491.15 vs. price of €30.80 (99.5% below fair value)
No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score
Get the complete analysis for FRA:5VT0
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VT0 has been successfully added to your 
